( October 20, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Amgen asked a US federal judge to certify for immediate appeal CareFirst's case accusing it of unlawfully delaying competition for its drug Enbrel after Amgen’s motion to dismiss was denied. Amgen argued that an immediate appeal to the US Court of Appeals for the Fourth Circuit would permit the legal framework for many key issues in the case to be clarified before the court and parties engage in resource intensive efforts, and even if it does not adopt Amgen’s position on the core issues, the Fourth Circuit could provide valuable guidance ahead of discovery, summary judgment, motions in limine, jury instructions, and trial.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.